| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | D53; hD53 |
| WB Predicted band size | 22 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human TPD52L1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于TPD52L1抗体的3篇文献示例(注：文献为模拟示例，实际引用需核实)：
---
1. **文献名称**: "TPD52L1 promotes tumor growth and is associated with poor prognosis in colorectal cancer"
**作者**: Zhang Y, et al.
**摘要**: 研究利用TPD52L1特异性抗体分析其在结直肠癌组织中的表达，发现TPD52L1高表达与肿瘤增殖和转移相关，可能通过激活MAPK信号通路促进癌症进展。
---
2. **文献名称**: "Characterization of a monoclonal antibody against TPD52L1 for detection of exosomal biomarkers"
**作者**: Wang L, et al.
**摘要**: 本研究开发了一种针对TPD52L1的新型单克隆抗体，验证其在细胞外囊泡(外泌体)中的检测能力，表明其可作为癌症液体活检的潜在工具。
---
3. **文献名称**: "TPD52L1 interacts with HER2 to modulate trastuzumab resistance in breast cancer"
**作者**: Smith J, et al.
**摘要**: 通过免疫共沉淀(使用TPD52L1抗体)发现TPD52L1与HER2的相互作用，揭示其在乳腺癌靶向治疗耐药性中的机制，为联合治疗提供新靶点。
---
如需具体文献，建议在PubMed或Web of Science中检索关键词“TPD52L1 antibody”或“TPD52L1 immunohistochemistry”获取最新研究。
The TPD52L1 antibody is a tool used to detect the Tumor Protein D52-Like 1 (TPD52L1), a member of the TPD52 protein family involved in cellular processes like vesicle trafficking, cell proliferation, and apoptosis. TPD52L1. encoded by the TPD52L1 gene, is overexpressed in various cancers, including breast, prostate, and lung cancers, making it a potential biomarker for tumor progression and therapeutic targeting. This protein interacts with signaling pathways such as mTOR and ERK, influencing cell survival and growth.
Antibodies against TPD52L1 are widely utilized in research to study its expression patterns, subcellular localization (e.g., Golgi apparatus, cytoplasmic vesicles), and functional roles through techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF). They help validate TPD52L1’s involvement in oncogenesis, drug resistance, and metastasis. Commercial TPD52L1 antibodies are typically raised in rabbits or mice, with validation across specific applications and species reactivity (human, mouse, rat). Researchers prioritize antibodies with high specificity, sensitivity, and reproducibility to minimize cross-reactivity with homologous family members (TPD52. TPD52L2. TPD52L3).
Ongoing studies aim to clarify TPD52L1’s mechanistic contributions to disease, supporting its potential as a diagnostic or prognostic marker and a target for anticancer therapies.
×
